These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment. Genazzani AD; Battaglia C; Gamba O; Petraglia F; Malavasi B; Genazzani AR J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414 [TBL] [Abstract][Full Text] [Related]
73. [Comprehensive approach to clinical background and effect of bromocriptine administration in patients with endocrinological polycystic ovarian disease]. Aisaka K; Kaneda S; Tsuzuki H; Tawada T; Kokuho K; Toriya Y; Nojima M; Yoshida K; Mori H Nihon Naibunpi Gakkai Zasshi; 1990 Feb; 66(2):101-12. PubMed ID: 2332079 [TBL] [Abstract][Full Text] [Related]
74. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? Dunaif A J Clin Endocrinol Metab; 1986 Jul; 63(1):215-21. PubMed ID: 3086357 [TBL] [Abstract][Full Text] [Related]
75. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. Lemay A; Faure N J Clin Endocrinol Metab; 1994 Dec; 79(6):1716-22. PubMed ID: 7989480 [TBL] [Abstract][Full Text] [Related]
76. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)]. Masaoka K; Kitazawa M; Kumasaka T Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437 [TBL] [Abstract][Full Text] [Related]
77. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries. Aono T; Miyazaki M; Miyake A; Kinugasa T; Kurachi K; Matsumoto K Acta Endocrinol (Copenh); 1977 Aug; 85(4):840-9. PubMed ID: 196471 [TBL] [Abstract][Full Text] [Related]
78. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986 [TBL] [Abstract][Full Text] [Related]
79. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. McCartney CR; Bellows AB; Gingrich MB; Hu Y; Evans WS; Marshall JC; Veldhuis JD Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E902-8. PubMed ID: 14736706 [TBL] [Abstract][Full Text] [Related]
80. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Levin JH; Carmina E; Lobo RA Fertil Steril; 1991 Oct; 56(4):635-40. PubMed ID: 1915936 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]